Literature DB >> 26800439

Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.

James S Wysock1, Neil Mendhiratta1, Fabio Zattoni1, Xiaosong Meng1, Marc Bjurlin1, William C Huang1, Herbert Lepor1, Andrew B Rosenkrantz2, Samir S Taneja3.   

Abstract

OBJECTIVES: To evaluate the cancer detection rates for men undergoing 12-core systematic prostate biopsy with negative prebiopsy multiparametric magnetic resonance imaging (mpMRI) results.
MATERIALS AND METHODS: Clinical data from consecutive men undergoing prostate biopsy who had undergone prebiopsy 3T mpMRI from December 2011 to August 2014 were reviewed from an institutional review board-approved prospective database. Men with negative prebiospy mpMRI results (negMRI) before biopsy were identified for the present analysis. Clinical features, cancer detection rates and negative predictive values were summarized.
RESULTS: Seventy five men with negMRI underwent systematic 12-core biopsy during the study period. In the entire cohort, men with no previous biopsy, men with previously negative biopsy and men enrolled in active surveillance protocols, the overall cancer detection rates were 18.7, 13.8, 8.0 and 38.1%, respectively, and the detection rates for Gleason score (GS) ≥7 cancer were 1.3, 0, 4.0 and 0%, respectively. The NPVs for all cancers were 81.3, 86.2, 92.0, and 61.9, and for GS ≥7 cancer they were 98.7, 100, 96.0 and 100%, respectively.
CONCLUSIONS: A negative prebiopsy mpMRI confers an overall NPV of 82% on 12-core biopsy for all cancer and 98% for GS ≥7 cancer. Based on biopsy indication, these findings assist in prebiopsy risk stratification for detection of high-risk disease and may provide guidance in the decision to pursue biopsy.
© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer detection; prostate MRI; prostate biopsy

Mesh:

Year:  2016        PMID: 26800439     DOI: 10.1111/bju.13427

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  36 in total

Review 1.  Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.

Authors:  Jonathan H Wang; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

2.  Ruling out clinically significant prostate cancer with negative multi-parametric MRI.

Authors:  Julie Y An; Abhinav Sidana; Sarah A Holzman; Joseph A Baiocco; Sherif Mehralivand; Peter L Choyke; Bradford J Wood; Baris Turkbey; Peter A Pinto
Journal:  Int Urol Nephrol       Date:  2017-11-15       Impact factor: 2.370

Review 3.  Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers.

Authors:  Matthew J Watson; Arvin K George; Mahir Maruf; Thomas P Frye; Akhil Muthigi; Michael Kongnyuy; Subin G Valayil; Peter A Pinto
Journal:  Future Oncol       Date:  2016-07-12       Impact factor: 3.404

4.  Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy.

Authors:  Akhil Muthigi; Arvin K George; Abhinav Sidana; Michael Kongnyuy; Richard Simon; Vanessa Moreno; Maria J Merino; Peter L Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2016-08-28       Impact factor: 7.450

Review 5.  PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway.

Authors:  Anwar R Padhani; Jelle Barentsz; Geert Villeirs; Andrew B Rosenkrantz; Daniel J Margolis; Baris Turkbey; Harriet C Thoeny; François Cornud; Masoom A Haider; Katarzyna J Macura; Clare M Tempany; Sadhna Verma; Jeffrey C Weinreb
Journal:  Radiology       Date:  2019-06-11       Impact factor: 11.105

6.  In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal US-guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers.

Authors:  Kareem K Elfatairy; Christopher P Filson; Martin G Sanda; Adeboye O Osunkoya; Sherif G Nour
Journal:  Radiol Imaging Cancer       Date:  2020-09-25

7.  Nonsuspicious prebiopsy multiparametric MRI: is prostate biopsy still necessary?

Authors:  Vassili Anastay; Bastien Gondran-Tellier; Robin McManus; Raphaelle Delonca; Akram Akiki; Sarah Gaillet; Veronique Delaporte; Marc Andre; Laurent Daniel; Gilles Karsenty; Eric Lechevallier; Romain Boissier; Michael Baboudjian
Journal:  Abdom Radiol (NY)       Date:  2020-09-09

Review 8.  Current Management Strategy for Active Surveillance in Prostate Cancer.

Authors:  Jamil S Syed; Juan Javier-Desloges; Stephanie Tatzel; Ansh Bhagat; Kevin A Nguyen; Kevin Hwang; Sarah Kim; Preston C Sprenkle
Journal:  Curr Oncol Rep       Date:  2017-02       Impact factor: 5.075

9.  A urologist's perspective on prostate cancer imaging: past, present, and future.

Authors:  Arvin K George; Baris Turkbey; Subin G Valayil; Akhil Muthigi; Francesca Mertan; Michael Kongnyuy; Peter A Pinto
Journal:  Abdom Radiol (NY)       Date:  2016-05

10.  MRI-targeted biopsy for detecting prostate cancer: have the guidelines changed our practices and our prostate cancer detection rate?

Authors:  Michael Baboudjian; Quentin Bandelier; Bastien Gondran-Tellier; Rony Abdallah; Floriane Michel; Pierre Clement Sichez; Eugenie Di-Crocco; Akram Akiki; Sarah Gaillet; Veronique Delaporte; Marc Andre; Laurent Daniel; Gilles Karsenty; Eric Lechevallier; Romain Boissier
Journal:  Int Urol Nephrol       Date:  2019-11-30       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.